Blood Flow and Metabolism in Locally Advanced Breast Cancer: Relationship to Response to Therapy
Locally advanced breast cancer (LABC) is commonly treated with neoadjuvant chemotherapy followed by definitive surgery. The factors influencing the response of LABC to presurgical chemotherapy are incompletely understood. To characterize in vivo tumor biology in patients with LABC, we measured preth...
Gespeichert in:
| Veröffentlicht in: | The Journal of nuclear medicine (1978) 2002-04, Vol.43 (4), p.500-509 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 509 |
|---|---|
| container_issue | 4 |
| container_start_page | 500 |
| container_title | The Journal of nuclear medicine (1978) |
| container_volume | 43 |
| creator | Mankoff, David A Dunnwald, Lisa K Gralow, Julie R Ellis, Georgiana K Charlop, Aaron Lawton, Thomas J Schubert, Erin K Tseng, Jeffrey Livingston, Robert B |
| description | Locally advanced breast cancer (LABC) is commonly treated with neoadjuvant chemotherapy followed by definitive surgery. The factors influencing the response of LABC to presurgical chemotherapy are incompletely understood. To characterize in vivo tumor biology in patients with LABC, we measured pretherapy blood flow and glucose metabolism in LABC, compared measurements with clinical and pathologic parameters, and examined blood flow and response to subsequent neoadjuvant chemotherapy.
Thirty-seven patients with newly diagnosed LABC underwent (18)F-FDG and (15)O-water PET imaging. Thirty-one of these patients underwent neoadjuvant chemotherapy, and response was evaluated by serial measurements of tumor size and pathologic examination after definitive surgery after chemotherapy. Tumor metabolism was estimated from graphic analysis of dynamic (18)F-FDG studies and was expressed as the metabolic rate of (18)F-FDG (MRFDG). Blood flow was estimated from dynamic images after bolus (15)O-water injection using a 1-compartment model. Tumor blood flow and metabolism were compared with clinical and pathologic parameters and with response to chemotherapy.
Both blood flow and metabolism were significantly higher in tumor than in normal breast. Tumor blood flow and metabolism were correlated but highly variable. There were weak associations of metabolism with patient age and tumor grade and of blood flow with estrogen receptor status. There was a statistically significant trend for patients with a high MRFDG to have a poorer response to therapy (P = 0.001). Response was not significantly correlated with any other parameters. A low ratio of MRFDG to blood flow was the best predictor of macroscopic complete response (CR) (P = 0.02 vs. non-CR). Preliminary analysis of patient follow-up showed the ratio of MRFDG to blood flow to also be predictive of disease-free survival.
Despite uniformly large tumor size, blood flow and metabolism in LABC are highly variable. High glucose metabolism predicts a poor response to neoadjuvant chemotherapy, and low MRFDG relative to blood flow is a predictor of CR. Further work is needed to elucidate the biologic mechanisms underlying these findings. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_71619943</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>113993011</sourcerecordid><originalsourceid>FETCH-LOGICAL-h295t-46d5ee5b9471ddd3da42eeb67835ef100ec42e871cf7b0f57c9d2dc747d7d9883</originalsourceid><addsrcrecordid>eNpdkF1LxDAQRYso7vrxFyQI-lZImqRpfNPFL1gRZH2uaTO1WdKmJq2y_94srgg-zdzhcBnOXjInnPKU57nYT-aY5CTlHPNZchTCGmOcF0VxmMwIkVRwyebJ2411TqM7676Q6jV6glFVzprQIdOjpauVtRt0rT9VX4NGNx5UGNFim_wVegGrRuP60JoBjS7mMMQE233VglfD5iQ5aJQNcLqbx8nr3e1q8ZAun-8fF9fLtM0kH1OWaw7AK8kE0VpTrVgGUOWioBwagjHU8VAIUjeiwg0XtdSZrgUTWmhZFPQ4ufzpHbz7mCCMZWdCDdaqHtwUShFdSMloBM__gWs3-T7-VmZEZlnOchyhsx00VR3ocvCmU35T_oqLwMUOUCE6anw0YsIfR7nkmcz-3mrNe_tlPJT9VFtQftu67jtGS1ZyjOk3wpSEuQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219226460</pqid></control><display><type>article</type><title>Blood Flow and Metabolism in Locally Advanced Breast Cancer: Relationship to Response to Therapy</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Mankoff, David A ; Dunnwald, Lisa K ; Gralow, Julie R ; Ellis, Georgiana K ; Charlop, Aaron ; Lawton, Thomas J ; Schubert, Erin K ; Tseng, Jeffrey ; Livingston, Robert B</creator><creatorcontrib>Mankoff, David A ; Dunnwald, Lisa K ; Gralow, Julie R ; Ellis, Georgiana K ; Charlop, Aaron ; Lawton, Thomas J ; Schubert, Erin K ; Tseng, Jeffrey ; Livingston, Robert B</creatorcontrib><description>Locally advanced breast cancer (LABC) is commonly treated with neoadjuvant chemotherapy followed by definitive surgery. The factors influencing the response of LABC to presurgical chemotherapy are incompletely understood. To characterize in vivo tumor biology in patients with LABC, we measured pretherapy blood flow and glucose metabolism in LABC, compared measurements with clinical and pathologic parameters, and examined blood flow and response to subsequent neoadjuvant chemotherapy.
Thirty-seven patients with newly diagnosed LABC underwent (18)F-FDG and (15)O-water PET imaging. Thirty-one of these patients underwent neoadjuvant chemotherapy, and response was evaluated by serial measurements of tumor size and pathologic examination after definitive surgery after chemotherapy. Tumor metabolism was estimated from graphic analysis of dynamic (18)F-FDG studies and was expressed as the metabolic rate of (18)F-FDG (MRFDG). Blood flow was estimated from dynamic images after bolus (15)O-water injection using a 1-compartment model. Tumor blood flow and metabolism were compared with clinical and pathologic parameters and with response to chemotherapy.
Both blood flow and metabolism were significantly higher in tumor than in normal breast. Tumor blood flow and metabolism were correlated but highly variable. There were weak associations of metabolism with patient age and tumor grade and of blood flow with estrogen receptor status. There was a statistically significant trend for patients with a high MRFDG to have a poorer response to therapy (P = 0.001). Response was not significantly correlated with any other parameters. A low ratio of MRFDG to blood flow was the best predictor of macroscopic complete response (CR) (P = 0.02 vs. non-CR). Preliminary analysis of patient follow-up showed the ratio of MRFDG to blood flow to also be predictive of disease-free survival.
Despite uniformly large tumor size, blood flow and metabolism in LABC are highly variable. High glucose metabolism predicts a poor response to neoadjuvant chemotherapy, and low MRFDG relative to blood flow is a predictor of CR. Further work is needed to elucidate the biologic mechanisms underlying these findings.</description><identifier>ISSN: 0161-5505</identifier><identifier>EISSN: 1535-5667</identifier><identifier>PMID: 11937594</identifier><identifier>CODEN: JNMEAQ</identifier><language>eng</language><publisher>Reston, VA: Soc Nuclear Med</publisher><subject>Adult ; Aged ; Antineoplastic agents ; Biological and medical sciences ; Blood Flow Velocity ; Breast Neoplasms - blood supply ; Breast Neoplasms - diagnostic imaging ; Breast Neoplasms - metabolism ; Breast Neoplasms - therapy ; Chemotherapy ; Chemotherapy, Adjuvant ; Disease-Free Survival ; Female ; Fluorodeoxyglucose F18 ; Glucose - metabolism ; Humans ; Medical sciences ; Middle Aged ; Oxygen Radioisotopes ; Pharmacology. Drug treatments ; Prognosis ; Radiopharmaceuticals ; Survival Analysis ; Tomography, Emission-Computed ; Water</subject><ispartof>The Journal of nuclear medicine (1978), 2002-04, Vol.43 (4), p.500-509</ispartof><rights>2002 INIST-CNRS</rights><rights>Copyright Society of Nuclear Medicine Apr 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13595292$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11937594$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mankoff, David A</creatorcontrib><creatorcontrib>Dunnwald, Lisa K</creatorcontrib><creatorcontrib>Gralow, Julie R</creatorcontrib><creatorcontrib>Ellis, Georgiana K</creatorcontrib><creatorcontrib>Charlop, Aaron</creatorcontrib><creatorcontrib>Lawton, Thomas J</creatorcontrib><creatorcontrib>Schubert, Erin K</creatorcontrib><creatorcontrib>Tseng, Jeffrey</creatorcontrib><creatorcontrib>Livingston, Robert B</creatorcontrib><title>Blood Flow and Metabolism in Locally Advanced Breast Cancer: Relationship to Response to Therapy</title><title>The Journal of nuclear medicine (1978)</title><addtitle>J Nucl Med</addtitle><description>Locally advanced breast cancer (LABC) is commonly treated with neoadjuvant chemotherapy followed by definitive surgery. The factors influencing the response of LABC to presurgical chemotherapy are incompletely understood. To characterize in vivo tumor biology in patients with LABC, we measured pretherapy blood flow and glucose metabolism in LABC, compared measurements with clinical and pathologic parameters, and examined blood flow and response to subsequent neoadjuvant chemotherapy.
Thirty-seven patients with newly diagnosed LABC underwent (18)F-FDG and (15)O-water PET imaging. Thirty-one of these patients underwent neoadjuvant chemotherapy, and response was evaluated by serial measurements of tumor size and pathologic examination after definitive surgery after chemotherapy. Tumor metabolism was estimated from graphic analysis of dynamic (18)F-FDG studies and was expressed as the metabolic rate of (18)F-FDG (MRFDG). Blood flow was estimated from dynamic images after bolus (15)O-water injection using a 1-compartment model. Tumor blood flow and metabolism were compared with clinical and pathologic parameters and with response to chemotherapy.
Both blood flow and metabolism were significantly higher in tumor than in normal breast. Tumor blood flow and metabolism were correlated but highly variable. There were weak associations of metabolism with patient age and tumor grade and of blood flow with estrogen receptor status. There was a statistically significant trend for patients with a high MRFDG to have a poorer response to therapy (P = 0.001). Response was not significantly correlated with any other parameters. A low ratio of MRFDG to blood flow was the best predictor of macroscopic complete response (CR) (P = 0.02 vs. non-CR). Preliminary analysis of patient follow-up showed the ratio of MRFDG to blood flow to also be predictive of disease-free survival.
Despite uniformly large tumor size, blood flow and metabolism in LABC are highly variable. High glucose metabolism predicts a poor response to neoadjuvant chemotherapy, and low MRFDG relative to blood flow is a predictor of CR. Further work is needed to elucidate the biologic mechanisms underlying these findings.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Blood Flow Velocity</subject><subject>Breast Neoplasms - blood supply</subject><subject>Breast Neoplasms - diagnostic imaging</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - therapy</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18</subject><subject>Glucose - metabolism</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Oxygen Radioisotopes</subject><subject>Pharmacology. Drug treatments</subject><subject>Prognosis</subject><subject>Radiopharmaceuticals</subject><subject>Survival Analysis</subject><subject>Tomography, Emission-Computed</subject><subject>Water</subject><issn>0161-5505</issn><issn>1535-5667</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpdkF1LxDAQRYso7vrxFyQI-lZImqRpfNPFL1gRZH2uaTO1WdKmJq2y_94srgg-zdzhcBnOXjInnPKU57nYT-aY5CTlHPNZchTCGmOcF0VxmMwIkVRwyebJ2411TqM7676Q6jV6glFVzprQIdOjpauVtRt0rT9VX4NGNx5UGNFim_wVegGrRuP60JoBjS7mMMQE233VglfD5iQ5aJQNcLqbx8nr3e1q8ZAun-8fF9fLtM0kH1OWaw7AK8kE0VpTrVgGUOWioBwagjHU8VAIUjeiwg0XtdSZrgUTWmhZFPQ4ufzpHbz7mCCMZWdCDdaqHtwUShFdSMloBM__gWs3-T7-VmZEZlnOchyhsx00VR3ocvCmU35T_oqLwMUOUCE6anw0YsIfR7nkmcz-3mrNe_tlPJT9VFtQftu67jtGS1ZyjOk3wpSEuQ</recordid><startdate>20020401</startdate><enddate>20020401</enddate><creator>Mankoff, David A</creator><creator>Dunnwald, Lisa K</creator><creator>Gralow, Julie R</creator><creator>Ellis, Georgiana K</creator><creator>Charlop, Aaron</creator><creator>Lawton, Thomas J</creator><creator>Schubert, Erin K</creator><creator>Tseng, Jeffrey</creator><creator>Livingston, Robert B</creator><general>Soc Nuclear Med</general><general>Society of Nuclear Medicine</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>4T-</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20020401</creationdate><title>Blood Flow and Metabolism in Locally Advanced Breast Cancer: Relationship to Response to Therapy</title><author>Mankoff, David A ; Dunnwald, Lisa K ; Gralow, Julie R ; Ellis, Georgiana K ; Charlop, Aaron ; Lawton, Thomas J ; Schubert, Erin K ; Tseng, Jeffrey ; Livingston, Robert B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h295t-46d5ee5b9471ddd3da42eeb67835ef100ec42e871cf7b0f57c9d2dc747d7d9883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Blood Flow Velocity</topic><topic>Breast Neoplasms - blood supply</topic><topic>Breast Neoplasms - diagnostic imaging</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - therapy</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18</topic><topic>Glucose - metabolism</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Oxygen Radioisotopes</topic><topic>Pharmacology. Drug treatments</topic><topic>Prognosis</topic><topic>Radiopharmaceuticals</topic><topic>Survival Analysis</topic><topic>Tomography, Emission-Computed</topic><topic>Water</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mankoff, David A</creatorcontrib><creatorcontrib>Dunnwald, Lisa K</creatorcontrib><creatorcontrib>Gralow, Julie R</creatorcontrib><creatorcontrib>Ellis, Georgiana K</creatorcontrib><creatorcontrib>Charlop, Aaron</creatorcontrib><creatorcontrib>Lawton, Thomas J</creatorcontrib><creatorcontrib>Schubert, Erin K</creatorcontrib><creatorcontrib>Tseng, Jeffrey</creatorcontrib><creatorcontrib>Livingston, Robert B</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of nuclear medicine (1978)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mankoff, David A</au><au>Dunnwald, Lisa K</au><au>Gralow, Julie R</au><au>Ellis, Georgiana K</au><au>Charlop, Aaron</au><au>Lawton, Thomas J</au><au>Schubert, Erin K</au><au>Tseng, Jeffrey</au><au>Livingston, Robert B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Blood Flow and Metabolism in Locally Advanced Breast Cancer: Relationship to Response to Therapy</atitle><jtitle>The Journal of nuclear medicine (1978)</jtitle><addtitle>J Nucl Med</addtitle><date>2002-04-01</date><risdate>2002</risdate><volume>43</volume><issue>4</issue><spage>500</spage><epage>509</epage><pages>500-509</pages><issn>0161-5505</issn><eissn>1535-5667</eissn><coden>JNMEAQ</coden><abstract>Locally advanced breast cancer (LABC) is commonly treated with neoadjuvant chemotherapy followed by definitive surgery. The factors influencing the response of LABC to presurgical chemotherapy are incompletely understood. To characterize in vivo tumor biology in patients with LABC, we measured pretherapy blood flow and glucose metabolism in LABC, compared measurements with clinical and pathologic parameters, and examined blood flow and response to subsequent neoadjuvant chemotherapy.
Thirty-seven patients with newly diagnosed LABC underwent (18)F-FDG and (15)O-water PET imaging. Thirty-one of these patients underwent neoadjuvant chemotherapy, and response was evaluated by serial measurements of tumor size and pathologic examination after definitive surgery after chemotherapy. Tumor metabolism was estimated from graphic analysis of dynamic (18)F-FDG studies and was expressed as the metabolic rate of (18)F-FDG (MRFDG). Blood flow was estimated from dynamic images after bolus (15)O-water injection using a 1-compartment model. Tumor blood flow and metabolism were compared with clinical and pathologic parameters and with response to chemotherapy.
Both blood flow and metabolism were significantly higher in tumor than in normal breast. Tumor blood flow and metabolism were correlated but highly variable. There were weak associations of metabolism with patient age and tumor grade and of blood flow with estrogen receptor status. There was a statistically significant trend for patients with a high MRFDG to have a poorer response to therapy (P = 0.001). Response was not significantly correlated with any other parameters. A low ratio of MRFDG to blood flow was the best predictor of macroscopic complete response (CR) (P = 0.02 vs. non-CR). Preliminary analysis of patient follow-up showed the ratio of MRFDG to blood flow to also be predictive of disease-free survival.
Despite uniformly large tumor size, blood flow and metabolism in LABC are highly variable. High glucose metabolism predicts a poor response to neoadjuvant chemotherapy, and low MRFDG relative to blood flow is a predictor of CR. Further work is needed to elucidate the biologic mechanisms underlying these findings.</abstract><cop>Reston, VA</cop><pub>Soc Nuclear Med</pub><pmid>11937594</pmid><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0161-5505 |
| ispartof | The Journal of nuclear medicine (1978), 2002-04, Vol.43 (4), p.500-509 |
| issn | 0161-5505 1535-5667 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71619943 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Aged Antineoplastic agents Biological and medical sciences Blood Flow Velocity Breast Neoplasms - blood supply Breast Neoplasms - diagnostic imaging Breast Neoplasms - metabolism Breast Neoplasms - therapy Chemotherapy Chemotherapy, Adjuvant Disease-Free Survival Female Fluorodeoxyglucose F18 Glucose - metabolism Humans Medical sciences Middle Aged Oxygen Radioisotopes Pharmacology. Drug treatments Prognosis Radiopharmaceuticals Survival Analysis Tomography, Emission-Computed Water |
| title | Blood Flow and Metabolism in Locally Advanced Breast Cancer: Relationship to Response to Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T13%3A13%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Blood%20Flow%20and%20Metabolism%20in%20Locally%20Advanced%20Breast%20Cancer:%20Relationship%20to%20Response%20to%20Therapy&rft.jtitle=The%20Journal%20of%20nuclear%20medicine%20(1978)&rft.au=Mankoff,%20David%20A&rft.date=2002-04-01&rft.volume=43&rft.issue=4&rft.spage=500&rft.epage=509&rft.pages=500-509&rft.issn=0161-5505&rft.eissn=1535-5667&rft.coden=JNMEAQ&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E113993011%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219226460&rft_id=info:pmid/11937594&rfr_iscdi=true |